US 9,809,802 B2
IBV strains and uses thereof
Wil Solano, Overland Park, KS (US); Brianna Ford, Lawrence, KS (US); and Chris Luther, Lenexa, KS (US)
Assigned to BIOMUNE COMPANY, Lenexa, KS (US)
Filed by BIOMUNE COMPANY, Lenexa, KS (US)
Filed on Oct. 5, 2015, as Appl. No. 14/875,171.
Prior Publication US 2017/0096644 A1, Apr. 6, 2017
Int. Cl. C12N 7/00 (2006.01); C12Q 1/70 (2006.01); C07K 14/005 (2006.01); A61K 39/00 (2006.01)
CPC C12N 7/00 (2013.01) [C07K 14/005 (2013.01); C12Q 1/701 (2013.01); A61K 39/00 (2013.01); C12N 2770/20021 (2013.01); C12N 2770/20022 (2013.01); C12N 2770/20034 (2013.01); C12N 2770/20061 (2013.01); C12N 2770/20071 (2013.01)] 14 Claims
 
1. An attenuated Infectious Bronchitis Virus (IBV), wherein said IBV (i) comprises a S1 gene having a nucleotide sequence with at least 99% identity to SEQ ID NO: 1, or the complementary strand thereof and (ii) confers protective immunity to at least two IBV serotypes selected from GA08, GA13 and DMV.